Effects of DPP4 Inhibition on COVID-19

Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04341935

Enrollment

Registered

2020-04-10

Start date

2021-06-30

Completion date

2021-12-30

Last updated

2021-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infection, Type 2 Diabetes

Keywords

COVID-19, SARS-Cov 2, DPP4, Type 2 diabetes

Brief summary

The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection

Interventions

DRUGLinagliptin

5 mg Linagliptin administered by mouth once daily

DRUGInsulin regimen

Standard of care insulin regimen as per hospital protocol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines * Age ≥ 18 * Confirmed COVID-19 * Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore throat, myalgia, nasal congestion, diarrhea * Moderate COVID-19 is defined as \> 2 of the following in non-intubated patients: any symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with bilateral ground glass opacities or bilateral consolidations, SpO2 \<90% up to 5L Nasal Cannula (NC) * No additional signs or symptoms of severe COVID-19.

Exclusion criteria

* Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines * History of Diabetic Ketoacidosis (DKA) * History of acute pancreatitis * Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73 m2

Design outcomes

Primary

Measure	Time frame	Description
Changes in Glucose Llevels	Baseline, up to 2 weeks	Change in glucose control will be assessed via glucose levels obtained from blood serum samples

Secondary

Measure	Time frame	Description
Changes in SpO2 levels	Baseline, up to 2 weeks	changes in SpO2 will be measured with a Pulseimetry, an indirect, non-invasive method
Changes in Interleukin 6 (IL6)	Baseline, up to 2 weeks	Changes in IL 6 will be assessed from blood serum samples
Changes in chest structures	Baseline, up to 2 weeks	Changes in Chest radiography (X-ray)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026